Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

A Potential Paradigm for the Robust and Systematic Prioritisation of Assets in Academic-Led, Multi-Industry Collaborative Trials in Rare Populations (Glo-BNHL)

Blood (2023) 142 (Supplement 1): 6247.

https://doi.org/10.1182/blood-2023-178724

Published: 2023

Journal Articles

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma (Glo-BNHL)

Blood (2023) 142 (Supplement 1): 3097.

https://doi.org/10.1182/blood-2023-178658

Published: 2023

Journal Articles

High Dose Methotrexate Does Not Reduce the Risk of CNS Relapse in Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma. Results of the Randomised Phase III Study UKALL 2011

Amy A. Kirkwood, Nicholas Goulden, John Moppett, Sujith Samarasinghe, Jon Mee, Rachael Hough, Pamela R. Kearns, Sarah Lawson, Clare J. Rowntree, Ajay Vora

Blood (2022) 140 (Supplement 1): 516–518.

https://doi.org/10.1182/blood-2022-160129

Published: 2022

Journal Articles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Blood (2019) 134 (Supplement_1): 1393.

https://doi.org/10.1182/blood-2019-125257

Published: 2019

Journal Articles

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy

Sara Ghorashian, FRCPath, PhD, Sujith Samarasinghe, Amy A Kirkwood, MSc, Rachael Hough, MD BMBS, FRCP, FRCPath, Clare Rowntree, MD, Sarah Lawson, MD, Nicholas John Goulden, MD PhD MRCPath, Emma Pond, PhD, Pamela R. Kearns, PhDFRCPC, Anthony V. Moorman, PhD, John Moppett, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 656.

https://doi.org/10.1182/blood-2018-99-118426

Published: 2018

Journal Articles

Intensified Dosing of Gemtuzumab Ozogamicin Can be Safely Combined with Induction Chemotherapy in Children with Acute Myeloid Leukaemia (AML) and High Risk Myelodysplasia (MDS)

Brenda Gibson, MD PhD, Aimee E Houlton, BSc, MSc, Andre Baruchel, MD, Guy Leverger, MD PhD, Owen P Smith, MD, Anna Lawson, BSc, Keith Wheatley, DPhil, Pamela R. Kearns, PhD FRCPC

Blood (2018) 132 (Supplement 1): 2681.

https://doi.org/10.1182/blood-2018-99-115899

Published: 2018

Journal Articles

Dexamethasone Pharmacokinetics Following Standard and Short Dosing Schedules in Patients on the UKALL2011 Trial

Rosanna Jackson, BSc, MSc, Philip Berry, BSc, Julie Errington, MSc, John Moppett, MD, Sujith Samarasinghe, Rachael Hough, MD BMBS, FRCP, FRCPath, Clare Rowntree, MD, Nicholas John Goulden, MD PhD MRCPath, Ajay Vora, MD, Pamela R. Kearns, PhDFRCPC, Julie Irving, PhD, Gareth J Veal, PhD

Blood (2017) 130 (Supplement 1): 101.

https://doi.org/10.1182/blood.V130.Suppl_1.101.101

Published: 2017

Journal Articles

UKALL 2011: Randomised Trial Investigating a Short Induction Dexamethasone Schedule for Children and Young Adults with Acute Lymphoblastic Leukaemia

Nicholas John Goulden, MD PhD MRCPath, Amy A Kirkwood, John Moppett, MD, Sujith Samarasinghe, Sarah Lawson, MD, Clare Rowntree, MD, Rachael Hough, MD BMBS, FRCP, FRCPath, Rajbir Athwal, Pamela R. Kearns, PhDFRCPC, Ajay Vora, MD

Blood (2017) 130 (Supplement 1): 141.

https://doi.org/10.1182/blood.V130.Suppl_1.141.141

Published: 2017

Journal Articles

Cytotoxicity of the Recombinant Human Arginase (BCT-100) Against Acute Myeloid Leukaemia (AML)

Francis J Mussai, MA(Oxon), BM, BCh, DPhil, Sharon Egan, Joseph Higginbotham-Jones, Anthony Lo, Margaret Ng, MD, Tracey A Perry, BSc, Justin Loke, Andrew D Beggs, BSC(Hons), MBBS, PhD, Guy Pratt, Pamela R Kearns, MBChB, PhD FRCPCH, Paul Cheng, MD PhD, Carmela DeSanto, PhD

Blood (2014) 124 (21): 2317.

https://doi.org/10.1182/blood.V124.21.2317.2317

Published: 2014

Journal Articles

The Sub-Clonal Complexity of STIL-TAL1 T-ALL

Caroline L Furness, MD, Marcela B Mansur, PhD, Victoria J Weston, PhD, Sarah Jenkinson, MSc, Frederik W van Delft, MDPhD, Lyndal Kearney, PhD, Ian Titley, PhD, Anthony M Ford, PhD, Rosemary E Gale, Pamela R Kearns, MBChB, PhD FRCPCH, Adolfo A. Ferrando, MD PhD, Christine J. Harrison, Nicola E Potter, PhD, Mel Greaves, FRS

Blood (2014) 124 (21): 3788.

https://doi.org/10.1182/blood.V124.21.3788.3788

Published: 2014

Journal Articles

An Analysis Of Mechanisms Of Central Nervous System Infiltration In Acute Lymphoblastic Leukaemia Using Primary Cells Xenografted Into Immunodeficient Mice

Blood (2013) 122 (21): 3866.

https://doi.org/10.1182/blood.V122.21.3866.3866

Published: 2013

Journal Articles

The EBV Oncogene LMP1 Protects Lymphoma Cells From Cell Death Through The Collagen-Mediated Activation Of Discoidin Domain Receptor 1

Fathima Zumla Cader, PhD, MBChB, MRCPCH, Martina Vockerodt, PhD, Shikha Bose, PhD, Eszter Nagy, BSc, Marie-Anne Brundler, MD, Pamela R Kearns, MBChB, PhD, FRCPCH, Paul G Murray, PhD

Blood (2013) 122 (21): 4241.

https://doi.org/10.1182/blood.V122.21.4241.4241

Published: 2013

Journal Articles

Clonal Evolution and Sub-Clonal Architecture In Paediatric T-Cell Acute Lymphoblastic Leukaemia (T-ALL)

Caroline L Furness, MD, Marcela B Mansur, PhD, Victoria J Weston, PhD, Frederik W Van Delft, MD PhD, Christine J Harrison, PhD, Lyndal Kearney, PhD, Anthony M Ford, PhD, Pamela R Kearns, MBChB, PhD, FRCPCH, Nicola E Potter, PhD, Jean Soulier, MD, PhD, Adolfo A. Ferrando, MD, PhD, Mel Greaves, PhD, FRS

Blood (2013) 122 (21): 1366.

https://doi.org/10.1182/blood.V122.21.1366.1366

Published: 2013

Journal Articles

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

Angelo Agathanggelou, PhD, Anastasia Zlatanou, PhD, Ahmed Gulshanara, MSc, Grant Stewart, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD, Guy Pratt, MD, Paul AH Moss, MD PhD, A. Malcolm R Taylor, PhD, Frederic Colland, PhD, Tatjana Stankovic, MD, PhD

Blood (2011) 118 (21): 3865.

https://doi.org/10.1182/blood.V118.21.3865.3865

Published: 2011

Journal Articles

Insight Into T-ALL Leukaemia Initiating Cells, Clonal Evolution and Impact of Treatment In Vivo Using Immune-Compromised Mouse Model,

Victoria J Weston, PhD, Tracey A Perry, BSc, Helen Roberts, BSc, Katie Brown, Shaun R Wilson, MBChB, MRCPCH, Pamela R Kearns, BSc, MBBCh, MRCP, PhD

Blood (2011) 118 (21): 3577.

https://doi.org/10.1182/blood.V118.21.3577.3577

Published: 2011

Journal Articles

Inhibition of BRD4 Bromodomains Is a Potent Novel Strategy to Target Apoptosis Resistance in Paediatric ALL

David Da Costa, Victoria J Weston, PhD, Wenbin Wei, PhD, Angelo Agathanggelou, PhD, Eva Petermann, PhD, Stefan Knapp, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD, Tatjana Stankovic, MD, PhD

Blood (2011) 118 (21): 77.

https://doi.org/10.1182/blood.V118.21.77.77

Published: 2011

Journal Articles

Characterisation of Leukaemic Stem Cell Populations in Childhood AML Indicate Distinct Disease Subtypes with Diverse Clinical Features

Victoria J Weston, PhD, Tracey A Perry, BSc, Katie Brown, Shaun R Wilson, MBChB, MRCPCH, Pamela R Kearns, BSc, MBBCh, MRCP, PhD

Blood (2011) 118 (21): 1500.

https://doi.org/10.1182/blood.V118.21.1500.1500

Published: 2011

Journal Articles

Tyrosine Kinase Inhibitor Screen Identifies the Multikinase Inhibitor, Foretinib, As a Sensitisor of Treatment-resistant B-Precursor ALL to Core Chemotherapeutic Agents

Shaun R Wilson, MBChB, MRCPCH, Victoria J Weston, PhD, Tatjana Stankovic, MD, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD

Blood (2011) 118 (21): 1509.

https://doi.org/10.1182/blood.V118.21.1509.1509

Published: 2011

Journal Articles

Dasatinib In Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase 1 Dose-Escalation Study of the Innovative Therapies for Children with Cancer (ITCC) Consortium

C. Michel Zwaan, Carmelo Rizzari, Francoise Mechinaud, Donna L Lancaster, MBChB, MRCPCH, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, Thomas Lehrnbecher, Vincent H. J. van der elden, H. Berna Beverloo, PhD, Monique L. den Boer, Rob Pieters, MD, PhD, Julie Rosenberg, Robert Herdlicka, Dominique Derreumaux, Shruti Agrawal, André Baruchel

Blood (2010) 116 (21): 2265.

https://doi.org/10.1182/blood.V116.21.2265.2265

Published: 2010

Journal Articles

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

David Da Costa, Victoria J Weston, PhD, Stefan Knapp, PhD, A. Malcolm R Taylor, PhD, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 3238.

https://doi.org/10.1182/blood.V116.21.3238.3238

Published: 2010

NARROW

A Potential Paradigm for the Robust and Systematic Prioritisation of Assets in Academic-Led, Multi-Industry Collaborative Trials in Rare Populations (Glo-BNHL)

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma (Glo-BNHL)

High Dose Methotrexate Does Not Reduce the Risk of CNS Relapse in Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma. Results of the Randomised Phase III Study UKALL 2011

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy

Intensified Dosing of Gemtuzumab Ozogamicin Can be Safely Combined with Induction Chemotherapy in Children with Acute Myeloid Leukaemia (AML) and High Risk Myelodysplasia (MDS)

Dexamethasone Pharmacokinetics Following Standard and Short Dosing Schedules in Patients on the UKALL2011 Trial

UKALL 2011: Randomised Trial Investigating a Short Induction Dexamethasone Schedule for Children and Young Adults with Acute Lymphoblastic Leukaemia

Cytotoxicity of the Recombinant Human Arginase (BCT-100) Against Acute Myeloid Leukaemia (AML)

The Sub-Clonal Complexity of STIL-TAL1 T-ALL

An Analysis Of Mechanisms Of Central Nervous System Infiltration In Acute Lymphoblastic Leukaemia Using Primary Cells Xenografted Into Immunodeficient Mice

The EBV Oncogene LMP1 Protects Lymphoma Cells From Cell Death Through The Collagen-Mediated Activation Of Discoidin Domain Receptor 1

Clonal Evolution and Sub-Clonal Architecture In Paediatric T-Cell Acute Lymphoblastic Leukaemia (T-ALL)

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

Insight Into T-ALL Leukaemia Initiating Cells, Clonal Evolution and Impact of Treatment In Vivo Using Immune-Compromised Mouse Model,

Inhibition of BRD4 Bromodomains Is a Potent Novel Strategy to Target Apoptosis Resistance in Paediatric ALL

Characterisation of Leukaemic Stem Cell Populations in Childhood AML Indicate Distinct Disease Subtypes with Diverse Clinical Features

Tyrosine Kinase Inhibitor Screen Identifies the Multikinase Inhibitor, Foretinib, As a Sensitisor of Treatment-resistant B-Precursor ALL to Core Chemotherapeutic Agents

Dasatinib In Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase 1 Dose-Escalation Study of the Innovative Therapies for Children with Cancer (ITCC) Consortium

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only